Endothelial cells, tissue factor and infectious diseases

Brazilian Journal of Medical and Biological Research

Volumn 36, Issue 8, 2003, Pages 987-991

  Lopes Bezerra, Leila M ^a   Filler, S G ^b  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endothelial cell; Fungus; Infectious diseases; Procoagulant activity; Tissue factor

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; MEMBRANE PROTEIN; PROCOAGULANT; THROMBOPLASTIN;

ASPERGILLOSIS; BACTERIAL ENDOCARDITIS; BLOOD CLOTTING; CELL ACTIVATION; CELL SURFACE; CELL TYPE; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FIBRIN CLOT; GRAFT REJECTION; GRANULOCYTE; HOMEOSTASIS; HOST CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFLAMMATION; MICROORGANISM; MONOCYTE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SEPSIS; SEPTIC SHOCK; SHORT SURVEY; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOSIS;

BACTERIA (MICROORGANISMS); FUNGI;

EID: 0042827417     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2003000800004     Document Type: Short Survey

References (49)

1. Drake TA, Morrissey JH & Edgington TS (1989). Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. American Journal of Pathology, 134: 1087-1097.
2. Wilcox JN, Smith KM, Shwartz SM & Gordon D (1989). Localization of tissue factor in the normal vessel wall and in atherosclerotic plaque. Proceedings of the National Academy of Sciences, USA, 86: 2839-2843.
3. Fleck RA, Rao LV, Rapaport SI & Varki SN (1990). Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thrombosis Research, 59: 421-437.
4. Nemerson Y (1988). Tissue factor and hemostasis. Blood, 71: 1-8.
5. Morrissey JH (2001). Tissue factor: an enzyme cofactor and a true receptor. Thrombosis and Haemostasis, 86: 66-74
6. Vallet B & Wiel E (2001). Endothelial cell dysfunction and coagulation. Critical Care Medicine, 29 (Suppl 7): S36-S41.
7. Doshi SN & Marmur JD (2002). Evolving role of tissue factor and its pathway inhibitor. Critical Care Medicine, 30 (Suppl 5): S241-S250.
8. 2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. Journal of Biological Chemistry, 270: 4650-4660.
9. Poulsen LK, Jacobsen N, Sorensen BB, Bergenhem NC, Kelly JD, Foster DC, Thastrup O, Ezban M & Petersen LC (1998). Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. Journal of Biological Chemistry, 273: 6228-6232.
10. Pendurthi UR & Rao LV (2002). Factor VIIa/tissue factor-induced signaling: a link between clotting and disease. Vitamins and Hormones, 64: 323-355.
11. Morrissey JH, Fakhrai H & Edgington TS (1987). Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell, 50: 129-135.
12. Paborsky LR, Tate KM, Harris RJ, Yansura DG, Band L, McCray G, Gorman CM, O'Brien DP, Chang JY & Swartz JR (1989). Purification of recombinant human tissue factor. Biochemistry, 28: 8072-8077.
13. Rapaport SI & Rao LV (1995). The tissue factor pathway: how it has become a "prima ballerina". Thrombosis and Haemostasis, 74: 7-17.
14. Broze Jr GJ, Leykam JE, Schwartz BD & Miletich JP (1985). Purification of human brain tissue factor. Journal of Biological Chemistry, 260: 10917-10920.
15. Stone MJ, Ruf W, Miles DJ, Edgington TS & Wright PE (1995). Recombinant soluble human tissue factor secreted by Saccharomyces cerevisiae and refolded from Escherichia coli inclusion bodies: glycosylation of mutants, activity and physical characterization. Biochemical Journal, 310: 605-614.
16. Bevilacqua MP, Pober JS, Majeau GR, Contran RS & Gimbrone MA (1984). Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. Journal of Experimental Medicine, 160: 618-623.
17. Edwards RL & Rickles FR (1984). Macrophage procoagulants. Progress in Hemostasis and Thrombosis, 7: 183-209.
18. Meszaros K, Aberle S, Dedrick R, Machovich R, Horwitz A, Birr C, Theofan G & Parent JB (1994). Monocyte tissue factor induction by lipopolysaccharide (LPS): dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability-increasing protein. Blood, 83: 2516-2525.
19. Mantovani A, Bussolino F & Introna M (1997). Cytokine regulation of endothelial cell function: from the molecular level to the bedside. Immunology Today, 18: 231-240.
20. Conway EM, Bach R, Rosenberg RD & Konigsberg WH (1989). Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thrombosis Research, 53: 231-241.
21. Ameri A, Kuppuswamy MN & Basu S (1992). Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood, 79: 3219-3226.
22. Chan EL, Haudek SB, Giroir BP & Murphy JT (2001). Human coronary endothelial cell activation by endotoxin is characterized by NF-kappaB activation and TNF-alpha synthesis. Shock, 16: 349-354.
23. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW & Radder JK (2002). Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation, 106: 2442-2447.
24. Le DT, Rapaport SI & Rao LV (1992). Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. Journal of Biological Chemistry, 267: 15447-15454.
25. Greeno EW, Bach RB & Moldow CF (1996). Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Laboratory Investigation, 75: 281-289.
26. Mulder AB, Smit JW, Bom VJ, Blom NR, Ruiters MH, Halie MR & van der Meer J (1996). Association of smooth muscle tissue factor with calveolae. Blood, 88: 1306-1313.
27. Rao LV & Rapaport SI (1988). Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proceedings of the National Academy of Sciences, USA, 85: 6687-6691.
28. Maruyama I (1998). Biology of endothelium. Lupus, 7 (Suppl 2): S41-S43.
29. Broze Jr GJ (1992). The role of tissue factor pathway inhibitor in a revised coagulation cascade. Seminars in Hematology, 29: 159-169.
30. Broze Jr GJ (1995). Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagulation and Fibrinolysis, 6 (Suppl 1): S7-S13.
31. Grinnell BW & Joyce D (2001). Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Critical Care Medicine, 29 (Suppl 7): S53-S58.
32. Esmon CT (2001). Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Critical Care Medicine, 29 (Suppl 7): S48-S51.
33. Esmon CT, Fukudome K, Mather T, Bode W, Regan LM, Stearns-Kurosawa DJ & Kurosawa S (1999). Inflammation, sepsis, and coagulation. Haematologica, 84: 254-259.
34. Healy DP (2002). New and emerging therapies for sepsis. Annals of Pharmacotherapy, 36: 648-654.
35. Kidokoro A, Iba T, Fukunaga M & Yagi Y (1996). Alterations in coagulation and fibrinolysis during sepsis. Shock, 5: 223-228.
36. Iba T, Kidokoro A & Yagi Y (1998). The role of the endothelium in changes in procoagulant activity in sepsis. Journal of the American College of Surgeons, 187: 321-329.
37. Esmon CT (1998) Inflammation and thrombosis. Mutual regulation by protein C. Immunologist, 6: 84-89.
38. Marshall JC (2001). Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Critical Care Medicine, 29 (Suppl 7): S99-S106.
39. Bernard GR, Vincent JL, Laterre PF et al. (2001). Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine, 344: 699-709.
40. Parrillo JE (1993). Pathogenic mechanisms of septic shock. New England Journal of Medicine, 328: 1471-1477.
41. van der Poll T, Büller HR, ten Cate H, Wortel CH, Bauer KA & van Deventer SJH (1990). Activation of coagulation after administration of tumor necrosis factor to normal subjects. New England Journal of Medicine, 322: 1622-1627.
42. Taylor Jr FB, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K & Edgington TS (1991). Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circulatory Shock, 33: 127-134.
43. Bancsi MJLM, Thompson J & Bertina RM (1994). Stimulation of monocyte tissue factor expression in an in vitro model of bacterial endocarditis. Infection and Immunity, 62: 5669-5672.
44. Veltrop MHAM, Thompson J & Beekhuizen H (2001). Monocytes augment bacterial species- and strain-dependent induction of tissue factor in human vascular endothelial cells. Infection and Immunity, 69: 2797-2807.
45. Veltrop MHAM, Beekhuizen H & Thompson J (1999). Bacterial species- and strain-dependent induction of tissue factor in human vascular endothelial cells. Infection and Immunity, 67: 6130-6138.
46. Veltrop MHAM & Beekhuizen H (2002). Monocytes maintain tissue factor activity after cytolysis of bacteria-infected endothelial cells in an in vitro model of bacterial endocarditis. Journal of Infectious Diseases, 186: 1145-1154.
47. Mattsson E, Herwald H, Björck L & Egesten A (2002). Peptidoglycan from Staphylococcus aureus induces tissue factor expression and procoagulant activity in human monocytes. Infection and Immunity, 70: 3033-3039.
48. Bodey GP & Vartivarian S (1989). Aspergillosis. European Journal of Microbiology and Infectious Diseases, 8: 413-437.
49. Rivers RP, Cattermole HE & Wright I (1992). The expression of surface tissue factor apoprotein by blood monocytes in the course of infections in early infancy. Pediatric Research, 31: 567-573.